Top

Breast Cancer Research and Treatment

Published in:

01-11-2012 | Letter to the Editor

A modified technology could significantly improve the visualization rate of the internal mammary sentinel lymph nodes in breast cancer patients

Authors: Peng-fei Qiu, Juan-juan Liu, Yan-bing Liu, Guo-ren Yang, Xiao Sun, Yong-sheng Wang

Published in: Breast Cancer Research and Treatment | Issue 1/2012

Excerpt

To the Editor, …

Postma EL, van Wieringen S, Hobbelink MG et al (2012) Sentinel lymph node biopsy of the internal mammary chain in breast cancer. Breast Cancer Res Treat 134:735–741PubMedCrossRef

Chen RC, Lin NU, Golshan M et al (2008) Internal mammary nodes in breast cancer: diagnosis and implications for patient management-a systematic review. J Clin Oncol 26:4981–4989PubMedCrossRef

Kong AL, Tereffe W, Hunt KK et al (2012) Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. Cancer. doi:10.1002/cncr.27564

Heuts EM, van der Ent FW, von Meyenfeldt MF et al (2009) Internal mammary lymph drainage and sentinel node biopsy in breast cancer: a study on 1008 patients. Eur J Surg Oncol 35:252–257PubMedCrossRef

Mudun A, Sanli Y, Ozmen V et al (2008) Comparison of different injection sites of radionuclide for sentinel lymph node detection in breast cancer: single institution experience. Clin Nucl Med 33:262–267PubMedCrossRef

Title: A modified technology could significantly improve the visualization rate of the internal mammary sentinel lymph nodes in breast cancer patients
Authors: Peng-fei Qiu
Juan-juan Liu
Yan-bing Liu
Guo-ren Yang
Xiao Sun
Yong-sheng Wang
Publication date: 01-11-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-2203-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2012

Cost effectiveness of new breast cancer radiotherapy technologies in diverse populations

Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer

A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer

Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype

Exposure to polychlorinated biphenyl (PCB) congeners measured shortly after giving birth and subsequent risk of maternal breast cancer before age 50

The Piper Fatigue Scale-12 (PFS-12): psychometric findings and item reduction in a cohort of breast cancer survivors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer